$3.37
0.00% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US03836J1025
Symbol
APRE

Aprea Therapeutics Inc Stock price

$3.37
+0.39 13.09% 1M
-0.72 17.60% 6M
-1.33 28.30% YTD
-0.33 8.92% 1Y
-60.83 94.75% 3Y
-987.23 99.66% 5Y
-406.63 99.18% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.00 0.00%
ISIN
US03836J1025
Symbol
APRE
Sector
Industry

Key metrics

Market capitalization $18.32m
Enterprise Value $-6.62m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 0.47
EV/Sales (TTM) EV/Sales -5.05
P/S ratio (TTM) P/S ratio 13.98
P/B ratio (TTM) P/B ratio 0.83
Revenue growth (TTM) Revenue growth 130.31%
Revenue (TTM) Revenue $1.31m
EBIT (operating result TTM) EBIT $-14.77m
Free Cash Flow (TTM) Free Cash Flow $-13.99m
Cash position $26.25m
EPS (TTM) EPS $-2.81
P/E forward negative
P/S forward 13.69
EV/Sales forward negative
Short interest 0.38%
Show more

Is Aprea Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Aprea Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Aprea Therapeutics Inc forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a Aprea Therapeutics Inc forecast:

Buy
100%

Financial data from Aprea Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1.31 1.31
130% 130%
100%
- Direct Costs 0.02 0.02
-
2%
1.29 1.29
-
98%
- Selling and Administrative Expenses 6.99 6.99
21% 21%
534%
- Research and Development Expense 9.05 9.05
48% 48%
691%
-15 -15
2% 2%
-1,126%
- Depreciation and Amortization 0.02 0.02
-
2%
EBIT (Operating Income) EBIT -15 -15
2% 2%
-1,127%
Net Profit -14 -14
2% 2%
-1,031%

In millions USD.

Don't miss a Thing! We will send you all news about Aprea Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aprea Therapeutics Inc Stock News

Neutral
GlobeNewsWire
18 days ago
Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea's experimental drug, ATRN-119, over a 24-hour daily cycle
Neutral
GlobeNewsWire
2 months ago
Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S.
Neutral
GlobeNewsWire
3 months ago
DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024.
More Aprea Therapeutics Inc News

Company Profile

Aprea Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company was founded by Vladimir Bykov, Klas Gota Wiman, Staffan Stromblad, Natalia Issaeva, Galina Selivanova, and Wenji Bao in 2002 and is headquartered in Boston, MA.

Head office United States
CEO Oren Gilad
Employees 7
Founded 2002
Website www.aprea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today